ADVFN US – Market Content Editor
-

Park Hotels & Resorts shares rise 1% after BMO upgrade
Park Hotels & Resorts (NYSE:PK) shares rose 1.0% in pre-market trading to $15.45 after BMO Capital Markets upgraded the lodging REIT to “Outperform” from “Market Perform” and increased its price target to $18 from $14. The new target represents approximately 17.6% upside from the stock’s previous closing price, according to the supplied information. Analyst price…
-

Andersen Group shares rise 3% after Baird raises price target
Andersen Group Corp (NYSE:ANDG) shares rose 3.0% in pre-market trading after Baird increased its price target on the stock to $64 from $57 while maintaining an “Outperform” rating. The analyst action comes ahead of Andersen Group’s next quarterly earnings report, which is scheduled for September 2, 2026. Baird’s $64 price target represents the firm’s assessment…
-

Opus Genetics shares rise 5.9% ahead of OPGx-BEST1 trial data
Opus Genetics Inc (NASDAQ:IRD) shares rose 5.9% in pre-market trading ahead of the scheduled release of three-month topline data from Cohort 1 of its OPGx-BEST1 Phase 1/2 clinical trial. The September 1, 2026 data release concerns OPGx-BEST1, a gene replacement therapy being evaluated in patients with Best Vitelliform Macular Dystrophy and Autosomal-Recessive Bestrophinopathy, two inherited…
-

Ormat Technologies shares rise 3% ahead of dividend payment
Ormat Technologies (NYSE:ORA) shares rose 3.0% in pre-market trading to $105.02 ahead of the geothermal and renewable energy company’s quarterly dividend payment and following its increased full-year revenue guidance. Ormat’s board declared a quarterly dividend of $0.12 per share, payable on September 2, 2026, to shareholders of record as of August 19. As the record…
-

Fractyl Health shares rise 2.8% ahead of Virtual Commercial Strategy Day
Fractyl Health (NASDAQ:GUTS) shares rose 2.8% in pre-market trading ahead of the company’s Virtual Commercial Strategy Day, scheduled for 11:00 AM ET on Tuesday. Management is expected to provide details on the planned commercial strategy and market opportunity for Revita®, the company’s procedural therapy being developed for weight maintenance following discontinuation of GLP-1 treatments. The…
-

Kroger shares fall 1.2% after Citi issues short-term downside watch
Kroger (NYSE:KR) shares fell 1.2% in pre-market trading after Citi placed the supermarket group on a short-term downside Catalyst Watch ahead of its second-quarter 2026 earnings report. Citi expects Kroger to report second-quarter earnings per share of $1.05, in line with the current consensus estimate. However, the firm said it sees an increased likelihood that…
-

Duolingo shares rise 3.8% after Evercore ISI upgrade
Duolingo (NASDAQ:DUOL) shares rose 3.8% in pre-market trading after Evercore ISI analyst Mark Mahaney upgraded the stock to “Outperform” from “In Line” and raised the firm’s price target to $210. Evercore based its revised target on a valuation of 20 times estimated 2028 EBITDA. The firm also increased its earnings forecasts, with its 2027 and…
-

Robinhood Markets shares rise 2.4% after Morgan Stanley upgrade
Robinhood Markets (NASDAQ:HOOD) shares rose 2.4% in pre-market trading after Morgan Stanley upgraded the fintech brokerage to “Overweight” from “Equalweight” and increased its price target to $150 from $124. Morgan Stanley analysts cited evidence that Robinhood’s expanding range of financial products is increasing the value generated from its existing customer base, including higher assets and…
-

Cimpress shares edge lower as broader U.S. markets decline
Cimpress (NASDAQ:CMPR) shares fell 0.5% in pre-market trading to $88.64 as major U.S. equity indices moved lower ahead of the opening bell. No new company-specific announcement was identified in the supplied information as a direct catalyst for the move. Cimpress shares were trading within a range of $87.40 to $89.99 and remained below their 52-week…
-

Capricor Therapeutics shares rise 2.5% following August FDA update
Capricor Therapeutics (NASDAQ:CAPR) shares rose 2.5% in pre-market trading to $10.16, following regulatory developments in August concerning the company’s biologics license application for deramiocel. No new company-specific announcement was identified in the supplied information as a direct catalyst for Tuesday’s move. In mid-August, the U.S. Food and Drug Administration indicated that it was willing to…